Stocks and Investing
Stocks and Investing
Fri, November 5, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, November 4, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tejas Savant Maintained (TXG) at Buy with Decreased Target to $205 on, Nov 4th, 2021
Tejas Savant of Morgan Stanley, Maintained "10x Genomics, Inc." (TXG) at Buy with Decreased Target from $215 to $205 on, Nov 4th, 2021.
Tejas has made no other calls on TXG in the last 4 months.
There are 2 other peers that have a rating on TXG. Out of the 2 peers that are also analyzing TXG, 1 agrees with Tejas's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Derik De Bruin of "B of A Securities" Downgraded from Strong Buy to Hold and Held Target at $180 on, Tuesday, September 14th, 2021
This is the rating of the analyst that currently disagrees with Tejas
- Patrick Donnelly of "Citigroup" Maintained at Strong Buy with Decreased Target to $220 on, Thursday, August 5th, 2021
Contributing Sources